Varex Imaging Corp. (VREX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the unaudited Form 10-Q for Varex Imaging Corporation for the quarter ended January 2, 2026. Varex designs, manufactures, and services X-ray imaging components for medical and industrial applications. The company operates two reportable segments: Medical (X-ray tubes, detectors, software) and Industrial (security inspection, non-destructive testing). The fiscal year 2026 is a 52-week period ending October 2, 2026.
Key Financial Metrics
| Metric (in millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues, net | $209.6 | $199.8 |
| Gross Profit | $69.8 | $68.5 |
| Gross Margin | 33.3% | 34.3% |
| Operating Income | $15.4 | $11.2 |
| Net Income (Varex) | $2.3 | $(0.3) |
| Diluted EPS | $0.05 | $(0.01) |
| Cash & Equivalents | $119.5 | $145.0 |
| Total Debt (net) | $367.6 | $367.5 |
| Operating Cash Flow | $(16.1) | $9.5 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4.9% year-over-year, driven primarily by the Industrial segment (+17.4%) due to higher sales of inspection products and digital detectors. The Medical segment remained flat (+0.1%).
- Profitability: The company returned to profitability with $2.3 million in net income compared to a $0.3 million loss in the prior year. Operating income improved to $15.4 million.
- Margin Pressure: Total gross margin declined to 33.3% from 34.3%. The Medical segment margin dropped to 31.8% due to increased material costs, while the Industrial segment margin improved to 36.7%.
- Cash Flow: Operating cash flow turned negative at $(16.1) million, a significant shift from the $9.5 million provided in the prior year. This was primarily due to a $30.1 million increase in inventory levels to meet anticipated demand and timing of payments.
- Geographic Mix: Americas revenue grew 16.9%, and EMEA grew 6.6%, while APAC revenue declined 6.8% due to decreased sales of X-ray tubes and detectors.
Outlook, Risks, and Management Commentary
- Trade Environment: Management highlights significant risks from tariffs and trade wars, particularly between the U.S. and China. These factors have increased costs and reduced competitiveness. The company is pursuing mitigation strategies but does not expect to fully offset these impacts.
- MOFCOM Investigations: Two investigations by China's Ministry of Commerce regarding medical X-ray tubes were suspended indefinitely in November 2025. If recommenced, they could negatively impact the business.
- Liquidity: The company maintains $154.8 million in availability under its Revolving Credit Facility. Senior Secured Notes totaling $368.0 million mature in October 2027, which management expects to refinance in fiscal year 2026.
- Backlog: Estimated total backlog as of January 2, 2026, was approximately $264 million.
- Subsequent Event: On January 20, 2026, the company committed to purchasing manufacturing equipment for approximately $7.3 million over a 3-year term.
Investor Verification Checklist
- Verify the sustainability of the inventory build-up ($30.1M increase) and its impact on future working capital needs.
- Monitor the status of the MOFCOM investigations in China and potential tariff escalations affecting the APAC region.
- Assess the ability to maintain gross margins in the Medical segment amidst rising material costs.
- Review the company's plan for refinancing the $368 million Senior Secured Notes maturing in 2027.
- Track the resolution of ongoing legal disputes regarding joint ventures (VEC and Saudi Arabia partnership).